ERBB2 and breast cancer: As expected, a higher rate of HER2-positive and triple-negative tumours in comparison to non-inflammatory breast cancer was observed, as well as a pCR rate of 23.6%, comparable to the pCR rate of 23.2% reported in the study of Van Uden et al.11.